Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation
Authors:
- Nianzhen AnNANianzhen An
- Hao WangHWHao Wang
- Yiwen GaoYGYiwen Gao
- Duan LiuDLDuan Liu
- Ting BianTBTing Bian
- Juanli ZhuJZJuanli Zhu
- Chao ChenCCChao Chen
- 1 May 2011
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (5) , 830-837
Abstract
CYP2C19 is a highly polymorphic enzyme that affects the metabolism of a wide range of therapeutic drugs. Almost all the identified alleles of CYP2C19 are derived from nonsynonymous single nucleotide polymorphisms (nsSNPs). The objective of this study was to functionally characterize 20 nsSNPs of CYP2C19, distributed throughout the entire coding region, most of which have not been thoroughly characterized. cDNAs of these variants were constructed and expressed in yeast cells. All variants had similar levels of apoprotein and holoprotein expression, except for CYP2C19.16 and D360N, which had significantly lower holoprotein levels than the wild-type (WT) CYP2C19 enzyme, and CYP2C19.5B, which showed only apoprotein. The activity of the CYP2C19 variants was investigated using two substrates, S-mephenytoin and omeprazole, and six different kinetic parameters were measured. CYP2C19.5B, CYP2C19.6, and CYP2C19.8 were found to be catalytically inactive. The entire dataset of the remaining 17 variants, together with the WT, was analyzed by multivariate analysis. This analysis indicated that CYP2C19.9, CYP2C19.10, CYP2C19.16, CYP2C19.18, CYP2C19.19, A161P, W212C, and D360N were substantially altered in catalytic properties in comparison with the WT, with each of these variants exhibiting either dramatically decreased catalytic activities or higher Km values. These results not only generally confirmed the function of previously reported variants but also identified additional reduced-function variants. These findings will greatly extend our understanding of CYP2C19 genetic polymorphisms in humans as well as facilitate the structure-function study of the CYP2C19 protein.Keywords
This publication has 42 references indexed in Scilit:
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent PlacementCirculation, 2010
- Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han ChineseThe Pharmacogenomics Journal, 2009
- A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapyBlood Cells, Molecules, and Diseases, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Important Amino Acid Residues that Confer CYP2C19 Selective Activity to CYP2C9The Journal of Biochemistry, 2008
- Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chipsPharmacogenetics and Genomics, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structureXenobiotica, 2002
- Identification of Human CYP2C19 Residues that Confer S-Mephenytoin 4‘-Hydroxylation Activity to CYP2C9Biochemistry, 2001